login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
GRI BIO INC (GRI) Stock News
USA
- NASDAQ:GRI -
US3622AW4030
-
Common Stock
1.69
USD
0 (0%)
Last: 11/14/2025, 6:28:23 PM
1.68
USD
-0.01 (-0.59%)
After Hours:
11/14/2025, 6:28:23 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
GRI Latest News, Press Relases and Analysis
All
Press Releases
2 months ago - By: Benzinga
- Mentions:
BRTX
ONCO
MBX
THAR
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
2 months ago - By: Benzinga
- Mentions:
IVA
COCP
ADXN
ANEB
...
12 Health Care Stocks Moving In Friday's Pre-Market Session
9 months ago - By: GRI Bio, Inc.
GRI Bio Announces Reverse Stock Split
2 months ago - By: GRI Bio, Inc.
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
2 months ago - By: GRI Bio, Inc.
GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
3 months ago - By: GRI Bio, Inc.
GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
4 months ago - By: GRI Bio, Inc.
GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
4 months ago - By: GRI Bio, Inc.
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
4 months ago - By: GRI Bio, Inc.
GRI Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
4 months ago - By: ACCESS Newswire
- Mentions:
AKTX
AMIX
CNSP
NVNO
...
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
5 months ago - By: GRI Bio, Inc.
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
5 months ago - By: GRI Bio, Inc.
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
6 months ago - By: GRI Bio, Inc.
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results
6 months ago - By: GRI Bio, Inc.
GRI Bio to Participate in the Virtual Investor Closing Bell Series
6 months ago - By: GRI Bio, Inc.
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
6 months ago - By: GRI Bio, Inc.
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
6 months ago - By: GRI Bio, Inc.
GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
6 months ago - By: GRI Bio, Inc.
GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
7 months ago - By: GRI Bio, Inc.
GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
8 months ago - By: GRI Bio, Inc.
GRI Bio Announces Closing of $5.0 Million Public Offering
8 months ago - By: GRI Bio, Inc.
GRI Bio Announces Pricing of $5.0 Million Public Offering
8 months ago - By: GRI Bio, Inc.
GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
8 months ago - By: GRI Bio, Inc.
GRI Bio Participates in a Virtual Investor CEO Connect Segment
8 months ago - By: GRI Bio, Inc.
GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)
8 months ago - By: GRI Bio, Inc.
GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule
9 months ago - By: GRI Bio, Inc.
GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
a year ago - By: GRI Bio, Inc.
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds
a year ago - By: GRI Bio, Inc.
GRI Bio to Participate in the Virtual Investor Closing Bell Series
a year ago - By: GRI Bio, Inc.
GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
a year ago - By: GRI Bio, Inc.
GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
Please enable JavaScript to continue using this application.